Oncology biologics — checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, and CAR-T cell therapies — have transformed cancer treatment across dozens of tumor types and collectively represent the largest and fastest-growing segment of the biopharmaceutical market. Regeneron's Libtayo cemiplimab, Amgen's bispecific antibodies Blincyto and Imdelltra, and Gilead's Trodelvy ADC represent the leading oncology biologic programs among the ten companies. The competitive intensity is extraordinary — over 1,000 oncology biologics are in clinical development globally, and differentiation requires novel mechanisms, combination strategies, and biomarker-selected patient populations.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Checkpoint Inhibitor Market
• ADC Commercial Landscape
• Bispecific Antibody Pipeline
• CAR-T in Oncology
• Amgen, Regeneron, Gilead Oncology Strategies
• Combination Immunotherapy
• Biomarker and Precision Oncology
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. Checkpoint Inhibitor Market
4. ADC Commercial Landscape
5. Bispecific Antibody Pipeline
6. CAR-T in Oncology
7. Amgen, Regeneron, Gilead Oncology Strategies
8. Combination Immunotherapy
9. Biomarker and Precision Oncology
10. Competitive Landscape
11. Competitive Landscape
12. Regional Market Analysis
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Pipeline Assessment 2025
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Pfizer
Novartis
Johnson & Johnson
Daiichi Sankyo
Seagen
AbbVie
